Company intelligence / Profile preview
ENTOD Pharmaceuticals
Mumbai, Maharashtra, Indiaentodpharma.com ↗
- Ownership
- Private
- Employees
- ~4999
- Development stage
- Commercial
01
Overview
ENTOD has multiple commercial products and recently received marketing authorization for 0.05% atropine eye drops (Myatro XL) for pediatric myopia control in India. They also developed PresVu eye drops for presbyopia and are working on human insulin eye drops for conditions like diabetic retinopathy.
- Therapeutic areas
- DermatologyOphthalmologyInfectious Diseases
- Modalities
- Small moleculesOphthalmic formulationsENT formulationsDermatological formulations
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Eyecirque Eye, Skin & Mind Wellness (stake ownership)
Beyond the preview
Go deeper on ENTOD Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENTOD Pharmaceuticals.